Moderna Stock: Speculative Buy for Aggressive Investors on mRNA Pipeline Growth to 2030
Moderna's mRNA pipeline, including cancer vaccines and a European comeback, could drive triple-digit EPS growth by 2030, earning a speculative buy rating.
Moderna (NASDAQ:MRNA) presents a high-risk, high-potential opportunity for aggressive investors, driven by its expansive mRNA technology pipeline. Key catalysts include late-stage clinical trials for personalized cancer vaccines in partnership with Merck, a potential Norovirus vaccine filing, and a strategic re-entry into the European market for its COVID-19 vaccine. Analysts project this pipeline could fuel triple-digit earnings per share (EPS) growth by 2030, significantly outpacing broader market expectations. The stock is rated a speculative buy, suitable only for portfolios that can withstand volatility given the binary outcomes of clinical trials and regulatory approvals inherent to biotech investing.